DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Category NVAX

Novavax Inc

Novavax ( $NVAX ) Q4 2025 and the Matrix-M platform

Q4 2025 finally shows what the long Novavax story on Merlintrader was pointing to: revenue above 1.1 billion dollars for the year, a clean return to GAAP profitability in the quarter, and a 2026–2028 roadmap where Sanofi, Pfizer and other partners, not Novavax alone, carry most of the execution risk around Matrix-M.

NVAX Novavax and Pfizer

The short version: Novavax is no longer just fighting for survival as a COVID single-product story. With Sanofi first and Pfizer now, Matrix-M is slowly turning into a royalty platform. The balance sheet is still tight and the story remains binary, but the “all-or-nothing” risk has shifted a bit more towards “long-duration option on partner execution”.

NVAX Novavax Inc at JPM CC

Why this NVAX update after JPM 2026
Novavax is a rare case where the narrative matters almost as much as the numbers. The company went from “late Covid vaccine laggard” to “maybe dead”, then back to life thanks to a sequence of deals and restructurings. The 44th J.P. Morgan Healthcare Conference was the moment where CEO John Jacobs tried to lock in a new story: Novavax as a lean, partner-driven, Matrix-M platform company with a visible (not guaranteed) path to sustainability.

NVAX Novavax, Inc

From going concern to platform story with a cult retail base
For a long stretch of 2023, Novavax was treated as a failed Covid trade. A late vaccine, production issues, a balance sheet that flirted with collapse and a market that moved on to other themes. On paper, the story should have ended there.